MATINAS BIOPHARMA HOLDINGS, INC. Proceeds from Issuance of Private Placement
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Proceeds from Issuance of Private Placement of $3.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2026-08-13
- MATINAS BIOPHARMA HOLDINGS, INC. proceeds from issuance of private placement for the quarter ending 2025-12-31 was $0.00.
- MATINAS BIOPHARMA HOLDINGS, INC. proceeds from issuance of private placement for the quarter ending 2025-09-30 was $0.00.
- MATINAS BIOPHARMA HOLDINGS, INC. proceeds from issuance of private placement for the quarter ending 2025-06-30 was $1.65M.
- MATINAS BIOPHARMA HOLDINGS, INC. proceeds from issuance of private placement for the quarter ending 2025-03-31 was $1.65M.
- MATINAS BIOPHARMA HOLDINGS, INC. proceeds from issuance of private placement for fiscal 2025 was $3.30M.
- MATINAS BIOPHARMA HOLDINGS, INC. proceeds from issuance of private placement for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
- MATINAS BIOPHARMA HOLDINGS, INC. proceeds from issuance of private placement for fiscal 2013 was $20.00K.
| Period end | Proceeds from Issuance of Private Placement 2 month | Proceeds from Issuance of Private Placement 3 month | Proceeds from Issuance of Private Placement 6 month | Proceeds from Issuance of Private Placement 9 month | Proceeds from Issuance of Private Placement 12 month | Proceeds from Issuance of Private Placement 32 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $0.00 derived: sum of 2 quarters · filed 2026-03-31 | $1.65M derived: sum of 3 quarters · filed 2026-08-13 | $3.30M 10-K · filed 2026-03-31 | ||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $1.65M derived: sum of 2 quarters · filed 2026-08-13 | $3.30M 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $1.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $3.30M 10-Q · filed 2026-08-13 | ||||
| 2025-03-31 | $1.65M 10-Q · filed 2026-05-08 | |||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31 | $0.00 10-K · filed 2015-03-31 | ||||
| 2014-09-30 | $0.00 10-Q · filed 2014-11-14 | |||||
| 2014-03-31 | $0.00 10-Q · filed 2014-06-06 | $0.00 derived: sum of 2 quarters · filed 2015-03-31 | $20.00K 10-Q · filed 2014-06-06 | |||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31 | $20.00K 10-K · filed 2015-03-31 | ||||
| 2013-09-30 | $20.00K 10-Q · filed 2014-11-14 | |||||
| 2013-08-31 | $1.25M 10-Q · filed 2014-06-06 | |||||
| 2013-03-31 | $0.00 10-Q · filed 2014-06-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |